Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant gender » significant concern (Expand Search), significant burden (Expand Search)
level » levels (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant gender » significant concern (Expand Search), significant burden (Expand Search)
level » levels (Expand Search)
-
1901
-
1902
-
1903
-
1904
-
1905
Unsupervised hierarchical clustering for benign samples only (nontreatment, STT, and LTT groups).
Published 2025Subjects: -
1906
-
1907
Combined Morphological and IHC Data: Combined Morphological and Immunohistochemistry Data.
Published 2025Subjects: -
1908
-
1909
Morphologic changes after dihydrotestosterone (DHT) treatment.1A: Diffuse lobular atrophy (20x).
Published 2025Subjects: -
1910
-
1911
-
1912
-
1913
Restricted cubic spline plots showing the association between changes in PAL and risk of CVD.
Published 2025Subjects: -
1914
Logistic Regression Analysis of the Association between PALs (MET-minutes/week) and CVD.
Published 2025Subjects: -
1915
-
1916
IHC Scores computer image analysis: Immunohistochemistry Scores and computer image analysis.
Published 2025Subjects: -
1917
-
1918
-
1919
-
1920
Evogliptin attenuates the pyroptotic cell death of VSMCs during CER treatment by decreasing the pyroptotic-associated genes and GSDM-D cleavage efficiency <i>in-vitro.</i>
Published 2025“…<p>(A) Bar graph showed EVO significantly decreased Lactate dehydrogenase (LDH) release in CER treated P<sub>i</sub>‐induced VSMCs. …”